SYRE

Spyre Therapeutics, Inc. (SYRE) | Rumor.io

Spyre Therapeutics

SYRE

Attention (50-day avg)0%

Attention rank (50-day avg)#1,312

Bullish sentiment (50-day avg)93%

Price to earnings ratio1.68

Market capitalization7.6B

Earnings per share-1.92

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-155.2M

Social

What share of all stock conversation is about SYRE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% +0

Aug 26

Spyre Therapeutics, Inc.'s Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases did not meet the company's internal bar to prioritize advancement of SPY072.
The topline results from the rheumatoid arthritis sub-study showed the magnitude of effect did not meet the target, leading to a decline in Spyre Therapeutics shares.
Spyre Therapeutics' valuation already assumes substantial success from the pipeline, and the latest RA results were not strong enough for the company to advance SPY072 as monotherapy.

Generated by AI

Sentiment

Of the messages about SYRE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +10.19	67.44% -19.52
Bearish	—	—	0% -10.19	32.56% +19.52

Bullish· Apr 13

Spyre Therapeutics' ($SYRE) drug SPY001 showed strong IBD results, improving symptoms and remission in trials, boosting shares and future outlook.
Analyst targets for $SYRE have been revised upwards, contributing to the stock's surge to a 3-year high and solidifying its position as a potential rival to Takeda's Entyvio.
$SYRE has significant growth potential, with the stock up 350% and showing no signs of exhaustion, making it a promising investment opportunity.

Bearish· Jun 23

$SYRE's price may be overvalued, with some estimates suggesting a value of only $0.18-$0.20.
Spyre Therapeutics, Inc. is at risk of delisting due to its cash-negative position and lack of income.
The stock may be subject to a reverse split following a planned offering of $210 million in Series A non-voting convertible preferred stock.

Generated by AI

Topics

Of the messages about SYRE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	87.88%	73.6%
Technical Analysis	100%	100%	3.03%	8.54%
Analysts	0%	0%	9.09%	5.33%
Earnings	0%	0%	0%	3.05%
Controversies	0%	0%	0%	0.34%
Macro	0%	0%	0%	9.14%

Community

Of the messages about SYRE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	88.89%	53.33%	63.59%	46.99%
Newcomers	11.11%	46.67%	36.41%	53.01%

Spyre Therapeutics (NasdaqGS:SYRE) reported positive 12-week induction data from Part A of its Phase 2 SKYLINE trial for SPY003. The Phase 2 study delivered clinical proof-of-concept for SPY003, the firm's anti-IL-23 therapy for ulcerative colitis. Management also reported biological proof-of-concept for all three immunology mechanisms in Spyre Therapeutics' inflammatory bowel disease portfolio. The positive 12-week SKYLINE Part A results for SPY003 and Spyre's IBD mechanisms deserve to be...

7d agoYahoo Finance

Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests

On September 8, Spyre Therapeutics (NASDAQ:SYRE) announced that SPY003, its anti-IL-23 antibody, hit its primary endpoint in Part A of the Phase 2 SKYLINE trial, posting a 10.0-point reduction in Robart’s Histopathology Index score at Week 12 with a p-value below 0.0001. That result matters because it closes out a run of three straight readouts. […]

13d agofinance.yahoo.com

Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?

Spyre Therapeutics, Inc. (NASDAQ:SYRE) reported September 8 results from 44 patients with moderately to severely active ulcerative colitis in the open-label Part A of the Phase 2 SKYLINE trial. At week 12, the mean Robarts Histopathology Index, a measure of tissue inflammation, declined by 10 points. Clinical remission, measured by the modified Mayo Score, was […]

19d agoYahoo Finance

Spyre Therapeutics at Wells Fargo conference: betting on combination biologics

19d agoInvesting.com

Spyre Therapeutics (SYRE) Receives a Rating Update from a Top Analyst

Detailed price information for Spyre Therapeutics Inc (SYRE-Q) from The Globe and Mail including charting and trades.

19d agoThe Globe and Mail

Spyre Therapeutics at Citi summit: bets on autoimmune combinations

20d agoInvesting.com

Also Discussed

Investors talking about SYRE also mention

#	Name	Attention
1	Nurix Therapeutics, Inc.NRIX	0%new
2	Edgewise Therapeutics Inc.EWTX	0%new
3	Evelo Biosciences Inc.EVLO	0%0
4	AHI - Advanced Health Intelligence Ltd	——
5	Minerva Surgical Inc.UTRS	0%0
6	MRUS - Merus N.V.	——
7	AVAC - Avalon Acquisition Inc.	——
8	Locafy LimitedLCFY	0%new
9	SGTX - Sigilon Therapeutics, Inc.	——
10	EDTX - EdtechX Holdings Acquisition Corp. II	——

Spyre Therapeutics, Inc.

Healthcare
Biotechnology

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing long-acting antibodies and antibody combinations for inflammatory bowel disease and other immune-mediated disorders. Spyre Therapeutics concentrates on advancing therapies designed to improve disease control, extend treatment durability, and simplify dosing for patients with ulcerative colitis, Crohn’s disease, and related rheumatic conditions. Its current pipeline centers on investigational antibody programs targeting key immune pathways, including α4β7, TL1A, and IL-23, with both standalone and combination approaches under development. The company is primarily engaged in biopharmaceutical research and clinical development, and its work is centered on creating next-generation immunology treatments for complex chronic diseases. Headquartered in Waltham, Massachusetts, Spyre Therapeutics serves as a specialized player in the biotech sector, where it contributes to the advancement of targeted therapies for gastrointestinal and immune-mediated diseases.

Website

Location

221 Crescent Street

Waltham, MA, 02453

United States

Social

What share of all stock conversation is about SYRE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% +0

Aug 26

Spyre Therapeutics, Inc.'s Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases did not meet the company's internal bar to prioritize advancement of SPY072.
The topline results from the rheumatoid arthritis sub-study showed the magnitude of effect did not meet the target, leading to a decline in Spyre Therapeutics shares.
Spyre Therapeutics' valuation already assumes substantial success from the pipeline, and the latest RA results were not strong enough for the company to advance SPY072 as monotherapy.

Generated by AI

Sentiment

Of the messages about SYRE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +10.19	67.44% -19.52
Bearish	—	—	0% -10.19	32.56% +19.52

Bullish· Apr 13

Spyre Therapeutics' ($SYRE) drug SPY001 showed strong IBD results, improving symptoms and remission in trials, boosting shares and future outlook.
Analyst targets for $SYRE have been revised upwards, contributing to the stock's surge to a 3-year high and solidifying its position as a potential rival to Takeda's Entyvio.
$SYRE has significant growth potential, with the stock up 350% and showing no signs of exhaustion, making it a promising investment opportunity.

Bearish· Jun 23

$SYRE's price may be overvalued, with some estimates suggesting a value of only $0.18-$0.20.
Spyre Therapeutics, Inc. is at risk of delisting due to its cash-negative position and lack of income.
The stock may be subject to a reverse split following a planned offering of $210 million in Series A non-voting convertible preferred stock.

Generated by AI

Topics

Of the messages about SYRE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	87.88%	73.6%
Technical Analysis	100%	100%	3.03%	8.54%
Analysts	0%	0%	9.09%	5.33%
Earnings	0%	0%	0%	3.05%
Controversies	0%	0%	0%	0.34%
Macro	0%	0%	0%	9.14%

Community

Of the messages about SYRE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	88.89%	53.33%	63.59%	46.99%
Newcomers	11.11%	46.67%	36.41%	53.01%

Spyre Therapeutics

Social

Aug 26

Sentiment

Bullish· Apr 13

Bearish· Jun 23

Topics

Community

News

What Does Spyre Therapeutics (SYRE) Part A Trial Success Mean For Ulcerative Colitis?

Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests

Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?

Spyre Therapeutics at Wells Fargo conference: betting on combination biologics

Spyre Therapeutics (SYRE) Receives a Rating Update from a Top Analyst

Spyre Therapeutics at Citi summit: bets on autoimmune combinations

Also Discussed

Spyre Therapeutics, Inc.

Company Information

Location

News

What Does Spyre Therapeutics (SYRE) Part A Trial Success Mean For Ulcerative Colitis?

Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests

Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?

Spyre Therapeutics at Wells Fargo conference: betting on combination biologics

Spyre Therapeutics (SYRE) Receives a Rating Update from a Top Analyst

Spyre Therapeutics at Citi summit: bets on autoimmune combinations

Also Discussed

Social

Aug 26

Sentiment

Bullish· Apr 13

Bearish· Jun 23

Topics

Community